Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Pharming Group N.V.
PHAR | US
16.64
USD-0.44
-2.58%
PHAR | US
About Pharming Group N.V.
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
23/04/2026
Close
16.64
Open
16.92
High
16.95
Low
16.64
Pharming Group N.V. a biopharmaceutical company develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States Europe and internationally. The company's commercialized product is RUCONEST a plasma-free rhC1INH protein replacement therapy for the treatment acute hereditary angioedema (HAE) attacks. It also engages in the development of leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome; OTL-105 an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE; and alpha-glucosidase therapy for the treatment of Pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research development manufacturing and commercialization of OTL-105. Pharming Group N.V. is headquartered in Leiden the Netherlands.
View LessPHAR | US
Risk
31.1
Sharpe
1.36
Luna's Score
54/100
Recommendation
Hold
Luna says (PHAR | US)
What's Working
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
Strong Sharpe Ratio (> 1.2)
What's not Working
Price Below SMA10D
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
32.1%1 month
31.1%3 months
58.7%6 months
67.6%Returns
Fundamental Ratios
PE
-
Fwd. PE
169.49
Price to book
2.81
Debt to equity
0.63
Debt to assets
0.32
Ent. to EBITDA
77.45
Ent. to rev.
2.01
PEG
-
Other Fundamentals
EBITDA
-5.04M
MarketCap
1.13B
MarketCap(USD)
1.13B
Div. yield
-
Op. margin
-4.21
Erngs. growth
-61.50
Rev. growth
35.00
Ret. on equity
-6.33
Short ratio
0.76
Short perc.
0.01
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
1.77
Range1M
2.85
Range3M
6.84
Volumes: Market Activity
Rel. volume
0.31
Price X volume
83.93K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 77.45 | - | Expensive |
| Ent. to Revenue | 2.01 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 2.81 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 58.71 | - | Par |
| Debt to Equity | 0.63 | -1.23 | Expensive |
| Debt to Assets | 0.32 | 0.25 | Expensive |
| Market Cap | 1.13B | - | Emerging |
